搜索
Redhill Biopharma Ltd
RDHL添加自选
0.812USD
-0.026-3.11%
收盘 07/02, 13:00（美东）报价延迟15分钟
4.14M总市值
亏损市盈率 TTM
关键数据
0.880今开
0.890最高
41.70K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
0.82%换手率
0.830昨收
0.810最低
6.92K成交额
亏损市盈率静
0.97市净率
0.00%股息率 TTM
-37.25%ROA
3.31052周最高
1.12量比
-8.27M净利润
5.09M总股本
-0.1000每股收益TTM
4.99Beta
-1708.61%ROE
0.71052周最低
9.63%振幅
100.00%毛利率
4.14M总市值
-3.04回报/风险
5.60%风险率
TradingKey Redhill Biopharma Ltd股票评分
单位: USD 更新时间: 2026-07-02操作建议
Redhill Biopharma Ltd当前公司基本面数据相对非常健康，增长潜力很大。当前估值低估，在药品行业排名134/157位。机构持股占比非常高，中期看，股价处于平稳状态。近一个月，市场表现非常差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Redhill Biopharma Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Redhill Biopharma Ltd亮点
亮点风险
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
业绩增长期
公司处于发展阶段，最新年度总收入286.00K美元
估值低估
公司最新PE估值-8.12，处于3年历史低位
机构加仓
最新机构持股504.44K股，环比增加40.77%
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
Redhill Biopharma Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Redhill Biopharma Ltd简介
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
公司代码RDHL
公司Redhill Biopharma Ltd
CEOBen-Asher (Dror)
网址https://www.redhillbio.com/
相关品种
热门品种
常见问题
Redhill Biopharma Ltd(RDHL)的当前股价是多少？
Redhill Biopharma Ltd(RDHL)的当前股价是 0.81。
Redhill Biopharma Ltd的股票代码是什么？
Redhill Biopharma Ltd的股票代码是RDHL。
Redhill Biopharma Ltd股票的52周最高点是多少？
Redhill Biopharma Ltd股票的52周最高点是3.31。
Redhill Biopharma Ltd股票的52周最低点是多少？
Redhill Biopharma Ltd股票的52周最低点是0.71。
Redhill Biopharma Ltd的市值是多少？
Redhill Biopharma Ltd的市值是4.14M。
Redhill Biopharma Ltd(RDHL)股票的每股收益（EPS TTM）是多少
Redhill Biopharma Ltd(RDHL)股票的每股收益（EPS TTM）是-0.10。